{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:48:43Z","timestamp":1792453723303,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100008966","name":"Francophone Society for Diabetes","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008966","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales d'Endocrinologie"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ando.2024.101676","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T16:47:00Z","timestamp":1733330820000},"page":"101676","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of therapeutic doses of prednisolone and other glucocorticoids on insulin secretion from human islets"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1444-3932","authenticated-orcid":false,"given":"Omolara Khadijat","family":"Tijani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Moreno-Lopez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8445-1157","authenticated-orcid":false,"given":"Isaline","family":"Louvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2888-5456","authenticated-orcid":false,"given":"Ana","family":"Acosta-Montalvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Coddeville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Gmyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Kerr-Conte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Pattou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Christine","family":"Vantyghem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Saponaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Bonner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9584-4294","authenticated-orcid":false,"given":"St\u00e9phanie","family":"Espiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ando.2024.101676_bib0325","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1530\/EJE-19-0305","article-title":"Fifteen-year nationwide trends in systemic glucocorticoid drug use in Denmark","volume":"181","author":"Laugesen","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.101676_bib0330","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/qjmed\/93.2.105","article-title":"Use of oral corticosteroids in the United Kingdom","volume":"93","author":"van Staa","year":"2000","journal-title":"QJM"},{"key":"10.1016\/j.ando.2024.101676_bib0335","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s00125-022-05666-w","article-title":"When therapeutic drugs lead to diabetes","volume":"65","author":"Feve","year":"2022","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2024.101676_bib0340","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.ando.2024.101676_bib0345","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.ando.2023.03.011","article-title":"Glucocorticoid-induced hyperglycemia and diabetes: Practical points","volume":"84","author":"Descours","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"key":"10.1016\/j.ando.2024.101676_bib0350","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: state of the art","volume":"4","author":"Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.ando.2024.101676_bib0355","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1172\/JCI115886","article-title":"Roles of insulin resistance and beta-cell dysfunction in dexamethasone-induced diabetes","volume":"90","author":"Ogawa","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2024.101676_bib0360","first-page":"E36","article-title":"Effects of morning cortisol elevation on insulin secretion and glucose regulation in humans","volume":"270","author":"Plat","year":"1996","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ando.2024.101676_bib0365","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1530\/EJE-09-1034","article-title":"Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men","volume":"162","author":"van Raalte","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ando.2024.101676_bib0370","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1210\/jcem-55-5-910","article-title":"Hypercortisolism and insulin resistance: comparative effects of prednisone, hydrocortisone, and dexamethasone on insulin binding of human erythrocytes","volume":"55","author":"Yasuda","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.101676_bib0375","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2337\/db17-1314","article-title":"Adaptive beta-cell neogenesis in the adult mouse in response to glucocorticoid-induced insulin resistance","volume":"68","author":"Courty","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.101676_bib0380","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1007\/s001250051251","article-title":"Insulin resistant subjects lack islet adaptation to short-term dexamethasone-induced reduction in insulin sensitivity","volume":"42","author":"Larsson","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2024.101676_bib0385","doi-asserted-by":"crossref","first-page":"6035","DOI":"10.1073\/pnas.89.13.6035","article-title":"The diabetogenic effects of glucocorticoids are more pronounced in low- than in high-insulin responders","volume":"89","author":"Wajngot","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ando.2024.101676_bib0390","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1210\/jcem-41-3-600","article-title":"Inhibitory effect of prednisone on insulin secretion in man: model for duplication of blood glucose concentration","volume":"41","author":"Kalhan","year":"1975","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.101676_bib0395","first-page":"E806","article-title":"Kinetics of dexamethasone-induced alterations of glucose metabolism in healthy humans","volume":"275","author":"Schneiter","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.ando.2024.101676_bib0400","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1210\/endo-106-2-547","article-title":"Effect of corticosterone on insulin and glucagon secretion by the isolated perfused rat pancreas","volume":"106","author":"Barseghian","year":"1980","journal-title":"Endocrinology"},{"key":"10.1016\/j.ando.2024.101676_bib0405","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1210\/endo-111-5-1648","article-title":"Direct effect of cortisol and cortisone on insulin and glucagon secretion","volume":"111","author":"Barseghian","year":"1982","journal-title":"Endocrinology"},{"key":"10.1016\/j.ando.2024.101676_bib0410","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.molmet.2019.12.012","article-title":"Glucocorticoid induces human beta cell dysfunction by involving riborepressor GAS5 LincRNA","volume":"32","author":"Esguerra","year":"2020","journal-title":"Mol Metab"},{"key":"10.1016\/j.ando.2024.101676_bib0415","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1074\/jbc.272.6.3216","article-title":"Dexamethasone induces posttranslational degradation of GLUT2 and inhibition of insulin secretion in isolated pancreatic beta cells. Comparison with the effects of fatty acids","volume":"272","author":"Gremlich","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ando.2024.101676_bib0420","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0168-8227(00)00229-1","article-title":"The effects of dexamethasone on insulin release and biosynthesis are dependent on the dose and duration of treatment","volume":"51","author":"Jeong","year":"2001","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ando.2024.101676_bib0425","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1172\/JCI119175","article-title":"Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets","volume":"99","author":"Lambillotte","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2024.101676_bib0430","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.metabol.2005.06.023","article-title":"Dexamethasone suppresses phospholipase C activation and insulin secretion from isolated rat islets","volume":"55","author":"Zawalich","year":"2006","journal-title":"Metabolism"},{"key":"10.1016\/j.ando.2024.101676_bib0435","doi-asserted-by":"crossref","first-page":"106555","DOI":"10.1016\/j.isci.2023.106555","article-title":"Glucocorticoid-mediated induction of ZBTB16 affects insulin secretion in human islets and EndoC-betaH1 beta-cells","volume":"26","author":"Karagiannopoulos","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.ando.2024.101676_bib0440","doi-asserted-by":"crossref","first-page":"278","DOI":"10.2337\/db16-1356","article-title":"Glucocorticoids reprogram beta-cell signaling to preserve insulin secretion","volume":"67","author":"Fine","year":"2018","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.101676_bib0445","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.61.8.718","article-title":"Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology","volume":"61","author":"Buttgereit","year":"2002","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ando.2024.101676_bib0450","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-197904020-00004","article-title":"Clinical pharmacokinetics of prednisone and prednisolone","volume":"4","author":"Pickup","year":"1979","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ando.2024.101676_bib0455","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/TP.0b013e3181d154ac","article-title":"Upgrading pretransplant human islet culture technology requires human serum combined with media renewal","volume":"89","author":"Kerr-Conte","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.ando.2024.101676_bib0460","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2337\/diab.37.4.413","article-title":"Automated method for isolation of human pancreatic islets","volume":"37","author":"Ricordi","year":"1988","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.101676_bib0465","doi-asserted-by":"crossref","DOI":"10.1177\/1559325818783932","article-title":"Pharmacokinetics and bioavailability study of a prednisolone tablet as a single oral dose in Bangladeshi healthy volunteers","volume":"16","author":"Bashar","year":"2018","journal-title":"Dose Response"},{"key":"10.1016\/j.ando.2024.101676_bib0470","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/jps.2600600705","article-title":"Sustained-release formulation of prednisolone administered orally to man","volume":"60","author":"D\u2019Arcy","year":"1971","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.ando.2024.101676_bib0475","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2125.1978.tb01664.x","article-title":"Prednisone or prednisolone for the treatment of chronic active hepatitis?. A comparison of plasma availability","volume":"5","author":"Davis","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ando.2024.101676_bib0480","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1365-2125.1975.tb02779.x","article-title":"Prednisolone levels in the plasma and urine: a study of two preparations in man","volume":"2","author":"English","year":"1975","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ando.2024.101676_bib0485","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/j.1552-4604.1988.tb03105.x","article-title":"Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses","volume":"28","author":"Ferry","year":"1988","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ando.2024.101676_bib0490","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1177\/00912700122012733","article-title":"Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race","volume":"41","author":"Magee","year":"2001","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ando.2024.101676_bib0495","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2125.1977.tb00792.x","article-title":"Plasma prednisolone levels from enteric and non-enteric coated tablets estimated by an original technique","volume":"4","author":"Morrison","year":"1977","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.ando.2024.101676_bib0500","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/gut.13.9.690","article-title":"Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding","volume":"13","author":"Powell","year":"1972","journal-title":"Gut"},{"key":"10.1016\/j.ando.2024.101676_bib0505","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01086151","article-title":"Comparative bioavailability: eight commercial prednisone tablets","volume":"4","author":"Sullivan","year":"1976","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.ando.2024.101676_bib0510","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/BF01065399","article-title":"Bioavailability of prednisolone tablets","volume":"5","author":"Tembo","year":"1977","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1016\/j.ando.2024.101676_bib0515","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/0002-9343(77)90233-9","article-title":"Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function","volume":"63","author":"Meikle","year":"1977","journal-title":"Am J Med"},{"key":"10.1016\/j.ando.2024.101676_bib0520","doi-asserted-by":"crossref","first-page":"E640","DOI":"10.1152\/ajpendo.00251.2015","article-title":"Dynamics of glucose-induced insulin secretion in normal human islets","volume":"309","author":"Henquin","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ando.2024.101676_bib0525","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1210\/endo.137.11.8895332","article-title":"Stable and diffusible pools of nucleotides in pancreatic islet cells","volume":"137","author":"Detimary","year":"1996","journal-title":"Endocrinology"},{"key":"10.1016\/j.ando.2024.101676_bib0530","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.2337\/dc09-9033","article-title":"International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes","volume":"32","author":"International Expert","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2024.101676_bib0535","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/j.1552-4604.1991.tb01906.x","article-title":"Pharmacokinetics and oral bioavailability of hydrocortisone","volume":"31","author":"Derendorf","year":"1991","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ando.2024.101676_bib0540","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1136\/ard-2022-223358","article-title":"Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Bergstra","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.ando.2024.101676_bib0545","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.2337\/dc23-0353","article-title":"Type 2 diabetes polygenic score predicts the risk of glucocorticoid-induced hyperglycemia in patients without diabetes","volume":"46","author":"Deutsch","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ando.2024.101676_bib0550","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-014-0282-9","article-title":"Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events","volume":"74","author":"Fardet","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.ando.2024.101676_bib0555","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1210\/endrev\/bnad016","article-title":"Treating the side effects of exogenous glucocorticoids; can we separate the good from the bad?","volume":"44","author":"Pofi","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2024.101676_bib0560","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41584-020-0370-z","article-title":"Views on glucocorticoid therapy in rheumatology: the age of convergence","volume":"16","author":"Buttgereit","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.ando.2024.101676_bib0565","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI104726","article-title":"Dissociation of corticotropin-suppressing activity from the eosinopenic and hyperglycemic activities of corticosteroid analogues","volume":"42","author":"Kendall","year":"1963","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2024.101676_bib0570","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.clinthera.2023.11.013","article-title":"The effect of different types of oral or intravenous corticosteroids on capillary blood glucose levels in hospitalized inpatients with and without diabetes","volume":"46","author":"Limbachia","year":"2024","journal-title":"Clin Ther"},{"key":"10.1016\/j.ando.2024.101676_bib0575","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.diabres.2015.02.010","article-title":"Risk factors for the development of glucocorticoid-induced diabetes mellitus","volume":"108","author":"Katsuyama","year":"2015","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.ando.2024.101676_bib0580","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1210\/er.2019-00088","article-title":"Genetic risk scores for diabetes diagnosis and precision medicine","volume":"40","author":"Udler","year":"2019","journal-title":"Endocr Rev"},{"key":"10.1016\/j.ando.2024.101676_bib0585","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1172\/JCI119743","article-title":"Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids","volume":"100","author":"Delaunay","year":"1997","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ando.2024.101676_bib0590","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1055\/s-0028-1092779","article-title":"Direct effect of corticosterone upon insulin secretion studied by three different techniques","volume":"11","author":"Billaudel","year":"1979","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.ando.2024.101676_bib0595","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/BF00456122","article-title":"Effect of adrenal steroids on insulin release from cultured rat islets of Langerhans","volume":"29","author":"Pierluissi","year":"1986","journal-title":"Diabetologia"},{"key":"10.1016\/j.ando.2024.101676_bib0600","doi-asserted-by":"crossref","first-page":"641","DOI":"10.4093\/dmj.2021.0220","article-title":"Assessment of insulin secretion and insulin resistance in human","volume":"45","author":"Park","year":"2021","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.ando.2024.101676_bib0605","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2337\/diab.35.1.44","article-title":"Abnormalities of insulin responses after ambient and previous exposure to glucose in streptozocin-diabetic and dexamethasone-treated rats. Role of hyperglycemia and increased B-cell demands","volume":"35","author":"Grill","year":"1986","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.101676_bib0610","doi-asserted-by":"crossref","first-page":"R49","DOI":"10.1530\/JOE-14-0373","article-title":"Glucocorticoid treatment and endocrine pancreas function: implications for glucose homeostasis, insulin resistance and diabetes","volume":"223","author":"Rafacho","year":"2014","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ando.2024.101676_bib0615","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1210\/endo-108-4-1414","article-title":"Species-related differences in steroid-binding specificity of glucocorticoid receptors in lung","volume":"108","author":"Giannopoulos","year":"1981","journal-title":"Endocrinology"},{"key":"10.1016\/j.ando.2024.101676_bib0620","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1159\/000129638","article-title":"IGF-1 protects against dexamethasone-induced cell death in insulin secreting INS-1 cells independent of AKT\/PKB phosphorylation","volume":"21","author":"Avram","year":"2008","journal-title":"Cell Physiol Biochem"},{"key":"10.1016\/j.ando.2024.101676_bib0625","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/ijms22020623","article-title":"Molecular mechanisms of glucocorticoid-induced insulin resistance","volume":"22","author":"Beaupere","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ando.2024.101676_bib0630","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2337\/db05-1220","article-title":"Dexamethasone induces cell death in insulin-secreting cells, an effect reversed by exendin-4","volume":"55","author":"Ranta","year":"2006","journal-title":"Diabetes"},{"key":"10.1016\/j.ando.2024.101676_bib0635","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cellsig.2011.06.002","article-title":"Prednisolone-induced beta cell dysfunction is associated with impaired endoplasmic reticulum homeostasis in INS-1E cells","volume":"23","author":"Linssen","year":"2011","journal-title":"Cell Signal"},{"key":"10.1016\/j.ando.2024.101676_bib0640","doi-asserted-by":"crossref","first-page":"e6417","DOI":"10.1371\/journal.pone.0006417","article-title":"Epithelial-mesenchymal transition in cells expanded in vitro from lineage-traced adult human pancreatic beta cells","volume":"4","author":"Russ","year":"2009","journal-title":"PLoS One"}],"container-title":["Annales d'Endocrinologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426624007595?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003426624007595?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T08:37:00Z","timestamp":1743928620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003426624007595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0003426624007595"],"URL":"https:\/\/doi.org\/10.1016\/j.ando.2024.101676","relation":{},"ISSN":["0003-4266"],"issn-type":[{"value":"0003-4266","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of therapeutic doses of prednisolone and other glucocorticoids on insulin secretion from human islets","name":"articletitle","label":"Article Title"},{"value":"Annales d'Endocrinologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ando.2024.101676","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101676"}}